tldrdaily.news logo
Tag

Retatrutide

All articles tagged with #retatrutide

Are Weight-Loss Drugs Too Effective? New Trials Spark Safety Questions
health17 days ago

Are Weight-Loss Drugs Too Effective? New Trials Spark Safety Questions

Trial results for Eli Lilly’s retatrutide show about 28.7% weight loss after 68 weeks, higher than current meds, but with 12–18% dropout due to side effects and some participants reporting they were losing too much weight. Health experts caution about malnutrition and disordered eating, advocating dosing that is tailored to the patient and kept at the lowest effective level as obesity becomes a chronic disease; Novo Nordisk’s CagriSema uses flexible dosing to manage safety as full data from the retatrutide trial await publication.

via The New York Times|
#cagrisema#glp-1#health
Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs
business1 month ago

Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs

Eli Lilly announced a $3.5 billion manufacturing plant in Pennsylvania’s Lehigh Valley to produce its next-generation obesity therapies, including the experimental drug retatrutide. The new facility, Lilly’s fourth major U.S. site, is slated to start this year and become operational in 2031, creating about 850 local jobs and 2,000 construction roles, as the company seeks to expand capacity amid strong GLP-1 market competition and ongoing push to secure drug supply.

via CNBC|
#business#eli-lilly#glp-1
Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss
health1 month ago

Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss

Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.

via Gizmodo|
#cagrisema#glp-1-therapy#health
"Retatrutide Treatment Shows Promising Weight Loss Effects in Comparison to Placebo"
health2 years ago

"Retatrutide Treatment Shows Promising Weight Loss Effects in Comparison to Placebo"

A phase 2 trial of retatrutide, a triple-hormone-receptor agonist, found that participants experienced significant reductions in body weight at week 48, with variability depending on the dose and the heterogeneity of obesity. Women had greater weight reductions than men, and those with a BMI of 35 or higher had greater weight reductions than those with a lower BMI. At week 48, a weight reduction of 5% or more occurred in 92% of participants who received 4 mg of retatrutide, compared to 27% of those who received placebo. Gastrointestinal symptoms were the most common adverse effects, mostly mild to moderate in severity. Further research is needed to investigate the efficacy and safety of retatrutide in treating obesity.

via Pharmacy Times|
#clinical-trial#health#obesity
"Breakthrough Weight-Loss Drug by Eli Lilly Surpasses Expectations"
pharmaceuticals2 years ago

"Breakthrough Weight-Loss Drug by Eli Lilly Surpasses Expectations"

Eli Lilly's experimental drug, retatrutide, has shown the greatest weight loss yet in a mid-stage trial, with patients experiencing a 24.2% reduction in weight. If successful in larger Phase 3 trials, the drug could position Lilly as a leader in the race to provide effective obesity treatments. However, the U.K.'s cost-effectiveness agency has rejected Eli Lilly's Mounjaro as a treatment for type 2 diabetes, citing the need for more evidence on clinical benefits and cost effectiveness. Mounjaro is expected to gain regulatory approval for obesity later this year and is part of a group of medications showing significant weight-loss results.

via STAT|
#eli-lilly#mounjaro#obesity-treatment